Apogee Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed September 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Fairmount Funds Management LLC filed an amended Schedule 13D/A regarding beneficial ownership in Apogee Therapeutics, Inc. (market cap ~$1.8B). The filing documents are dated 2026-09-03. Specific share count, percentage ownership, acquisition date, and changes to the prior filing are not disclosed in the available text excerpt.
Why this rating
Schedule 13D/A amendments are routine ownership disclosures. No material transaction, stake change, or corporate action details provided; insufficient information to assess material impact.
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.